| scholarly article | Q13442814 |
| P50 | author | Everett E Vokes | Q73567428 |
| P2093 | author name string | S Mani | |
| H L Kindler | |||
| R C Donehower | |||
| M Aklilu | |||
| P433 | issue | 8 | |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 1270-1273 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Phase II study of flavopiridol in patients with advanced colorectal cancer | |
| P478 | volume | 14 |
| Q41993498 | A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model |
| Q36363971 | A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors |
| Q41900653 | A novel liposomal formulation of flavopiridol |
| Q37354482 | A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol |
| Q36187034 | Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer |
| Q34147910 | Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways |
| Q43413399 | Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer |
| Q37987789 | Cyclin dependent kinases in cancer: potential for therapeutic intervention |
| Q38369468 | Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers |
| Q37407079 | Cyclin-dependent kinase inhibitors as potential targeted anticancer agents |
| Q81086253 | Cyclin-dependent kinases as targets for cancer therapy |
| Q24201407 | Dietary flavonoid for preventing colorectal neoplasms |
| Q35615823 | Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia |
| Q93079092 | Highlights in Resistance Mechanism Pathways for Combination Therapy |
| Q33219702 | Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells |
| Q43093974 | In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity |
| Q37707220 | In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening |
| Q40427567 | Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines |
| Q47316489 | Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. |
| Q39125016 | Inhibitors of cyclin-dependent kinases as cancer therapeutics |
| Q46761522 | Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissues |
| Q33333952 | Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis |
| Q35741932 | New systemic frontline treatment for metastatic colorectal carcinoma |
| Q38089157 | New target agents in the treatment of colorectal cancer patients |
| Q33952759 | Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias |
| Q35445919 | Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS. |
| Q93202753 | Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process |
| Q36918131 | Protein kinases as targets for cancer treatment. |
| Q64117292 | RANBP9 suppresses tumor proliferation in colorectal cancer |
| Q36120794 | Recent progress in the discovery and development of cyclin-dependent kinase inhibitors |
| Q45080019 | Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle. |
| Q35642631 | Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents |
| Q92524896 | Targeting CDK9 for treatment of colorectal cancer |
| Q37923861 | The CDK inhibitors in cancer research and therapy. |
Search more.